SIGY (Sigyn Therapeutics) EPS (Basic) : $-2.31 (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics EPS (Basic)?

Sigyn Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.42. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.31.

Sigyn Therapeutics's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.31.

Sigyn Therapeutics's EPS without NRI for the three months ended in Mar. 2025 was $-0.42. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -2.33.

During the past 3 years, the average EPS without NRI Growth Rate was 0.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 34.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Sigyn Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 74.30% per year. The lowest was -88.50% per year. And the median was 15.60% per year.

Sigyn Therapeutics EPS (Basic) Historical Data

The historical data trend for Sigyn Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics EPS (Basic) Chart

Sigyn Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-6.80

-3.20

-3.13

-3.77

-2.51

Sigyn Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial															-0.62	-0.70	-0.94	-0.25	-0.42

Sigyn Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sigyn Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.34	-	0)	/	1.332
	=	-2.51

Sigyn Therapeutics's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.669	-	0)	/	1.605
	=	-0.42

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.31

Sigyn Therapeutics (OTCPK:SIGY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sigyn Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigyn Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106

Website

https://www.sigyntherapeutics.com

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Executives

Joseph Segelman	director, 10 percent owner, officer: President & CEO	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp	10 percent owner	9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman	director, officer: Secretary	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212